Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Advaxis, City of Hope collaborate on leukemia, lymphoma vaccines
September 2009
SHARING OPTIONS:

NORTH BRUNSWICK, N.J.Advaxis Inc., a developer of live, attenuated Listeria monocytogenes (Lm) vaccines, announced in August that it will collaborate with investigators at City of Hope on the development of a vaccine for the treatment of certain forms of leukemia and lymphoma. City of Hope investigators are studying a vaccine provided by Advaxis directed against the tumor-associated antigen WT-1. This molecule is observed to be over-expressed in certain cancers of the blood as well as some solid tumors such as breast, pancreas and brain cancers, which makes it a potential target for a selective immune attack delivered via an Lm vector designed by Advaxis. Financial details were not released.          

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.